Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition

Key Points

• Cardiovascular risk is increased in individuals with obesity and atherosclerotic cardiovascular disease, and evolocumab shows promise in mitigating this risk.
• The analysis indicates a meaningful impact of evolocumab on reducing major adverse cardiovascular events (MACE) associated with obesity.
• Assessment using clinical data highlights the benefit of PCSK9 inhibition in patients with elevated cardiovascular risk due to obesity and atherosclerosis.
• These findings suggest that pharmacotherapy targeting PCSK9 could enable better cardiovascular outcomes for obese individuals with heart disease.